With only around 2% of patients in the US currently receiving pharmacological obesity treatment, an oral option could significantly enhance adherence
In the AMY study, bothersome hot flushes rose from 8.8% before menopause to 37.3% in late perimenopause the same years many people are on a GLP-1
In patients treated with semaglutide a significant reduction of all-cause (HR, 0.84
A crossover study of 10 individuals with T2DM given three single dose interventions on three different days a week apart (either metformin 1g plus placebo subcutaneous injection
There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop, said senior author Ziyad Al-Aly, M.D., a clinical epidemiologist at Washington University School of Medicine and chief of the Research and Development Service at the VA St
Many people experience B12 deficiencies that can lead to fatigue, cognitive issues, and weakened immune function